Bionano Genomics (BNGO) investor relations material

Executive summary

• Q2 2026 revenue grew 21% year-over-year to $8.2 million, driven by increased clinical adoption, higher instrument and consumable sales, and global expansion, especially in Europe.

• Consumables revenue rose 31% year-over-year, with 9,219 flow cells sold, reflecting strong demand and increased utilization among existing clinical customers.

• Leadership strengthened with the return of Dr. Alex Hastie as Chief Scientific Officer.

• The installed base of OGM systems grew 5% year-over-year to 397 units as of June 30, 2026.

• Net loss for Q2 2026 was $7.4 million, compared to $6.9 million in Q2 2025.

Financial highlights

• Q2 2026 revenue was $8.2 million, up from $6.7 million in Q2 2025, with product revenue at $7.7 million and consumables revenue at $4.3 million.

• Sold 9,219 nanochannel array flow cells, up 27% year-over-year.

• Gross margin improved to 53% in Q2 2026, up from 52% in Q2 2025.

• Adjusted operating expense was $8.7 million, nearly flat year-over-year; GAAP operating expenses were $11.5 million, up 2% year-over-year.

• Cash, cash equivalents, and investments totaled $9.9 million as of June 30, 2026, with a cash runway into at least Q1 2027.

Outlook and guidance

• Full-year 2026 revenue guidance raised to $31–$33 million, with Q3 2026 guidance at $8.2–$8.6 million.

• Sequential Q3 growth expected to be modest due to timing of large orders and ongoing supply constraints.

• Most future growth expected from increased utilization by existing clients.

• Management expects continued operating losses and negative cash flows for at least the next year; additional capital will be required to fund operations.